Skip to main content
TipRanks
Go Ultimate75% OFF

Jazz Pharmaceuticals (J7Z) Stock Statistics & Valuation Metrics

0 Followers

Total Valuation

Jazz Pharmaceuticals has a market cap or net worth of CHF 12.80B. The enterprise value is CHF 17.77B.

Market Cap
CHF 12.80B
Enterprise Value
CHF 17.77B

Share Statistics

Jazz Pharmaceuticals has 64,189,050 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
64,189,050
Owned by Insiders
3.37%
Owned by Institutions
95.57%

Financial Efficiency

Jazz Pharmaceuticals’s return on equity (ROE) is -0.08 and return on invested capital (ROIC) is 1.22%.

Return on Equity (ROE)
-0.08
Return on Assets (ROA)
-0.03
Return on Invested Capital (ROIC)
1.22%
Return on Capital Employed (ROCE)
0.02
Revenue Per Employee
1.48M
Profits Per Employee
-123.23K
Employee Count
2,890
Asset Turnover
0.37
Inventory Turnover
1.21

Valuation Ratios

The current PE Ratio of Jazz Pharmaceuticals is 66.05. Jazz Pharmaceuticals’s PEG ratio is 0.04.

PE Ratio
66.05
PS Ratio
3.22
PB Ratio
3.65
Price to FCF
9.65
Price to Operating Cash Flow
9.04
PEG Ratio
0.04

Income Statement

In the last 12 months, Jazz Pharmaceuticals had revenue of 4.27B and earned -356.15M in profits. Earnings per share was -5.84.

Revenue
4.27B
Gross Profit
3.76B
Operating Income
224.42M
Pretax Income
-628.59M
Net Income
-356.15M
EBITDA
262.76M
Earnings Per Share (EPS)
-5.84

Cash Flow

In the last 12 months, operating cash flow was 1.69B and capital expenditures -119.73M, giving a free cash flow of 1.57B billion.

Operating Cash Flow
1.69B
Free Cash Flow
1.57B
Free Cash Flow per Share
24.31

Dividends & Yields

Jazz Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
10.37%
Earnings Yield
1.35%

Stock Price Statistics

Beta
0.22
52-Week Price Change
―
50-Day Moving Average
―
200-Day Moving Average
―
Relative Strength Index (RSI)
―
Average Volume (3m)
―

Important Dates

Jazz Pharmaceuticals upcoming earnings date is Mar 02, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 02, 2026
Next Earnings Date
Mar 02, 2027
Ex-Dividend Date
―

Financial Position

Jazz Pharmaceuticals as a current ratio of 1.86, with Debt / Equity ratio of 125.59%

Current Ratio
1.86
Quick Ratio
1.67
Debt to Market Cap
0.52
Net Debt to EBITDA
15.34
Interest Coverage Ratio
1.15

Taxes

In the past 12 months, Jazz Pharmaceuticals has paid -272.44M in taxes.

Income Tax
-272.44M
Effective Tax Rate
0.43

Enterprise Valuation

Jazz Pharmaceuticals EV to EBITDA ratio is 16.06, with an EV/FCF ratio of 11.94.

EV to Sales
3.98
EV to EBITDA
16.06
EV to Free Cash Flow
11.94
EV to Operating Cash Flow
11.10

Balance Sheet

Jazz Pharmaceuticals has CHF 2.86B in cash and marketable securities with CHF 5.64B in debt, giving a net cash position of -CHF 2.79B billion.

Cash & Marketable Securities
CHF 2.86B
Total Debt
CHF 5.64B
Net Cash
-CHF 2.79B
Net Cash Per Share
-CHF 43.44
Tangible Book Value Per Share
-CHF 27.58

Margins

Gross margin is 88.17%, with operating margin of 20.30%, and net profit margin of 4.37%.

Gross Margin
88.17%
Operating Margin
20.30%
Pretax Margin
5.50%
Net Profit Margin
4.37%
EBITDA Margin
24.79%
EBIT Margin
9.56%

Analyst Forecast

The average price target for Jazz Pharmaceuticals is CHF 253.86, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
CHF 253.86
Price Target Upside
―
Analyst Consensus
Strong Buy
Analyst Count
17
Revenue Growth Forecast
6.58%
EPS Growth Forecast
―

Scores

Smart Score
10
AI Score
―